MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer

This is an investigator-initiated, prospective, national multi-center, phase III, randomized, open-label, non-inferiority clinical study. The hypothesis is that using online adaptive radiotherapy technology for moderately fractionated radiotherapy in post-operative patients with cervical/endometrial cancer may reduce radiotherapy-related toxicity and improve quality of life while ensuring target coverage. The objective is to evaluate treatment-related toxicity and efficacy of moderately fractionated online adaptive radiotherapy compared to conventionally fractionated intensity-modulated radiot

Trial Details

NCT ID
NCT07584161
Phase
NA
Sponsor
Xiaorong Hou
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Moderately fractionated radiotherapy using online adaptive radiotherapy technology
  • Conventionally fractionated radiotherapy using image-guided intensity-modulated radiotherapy technology.
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Participants must be fully voluntary and have decision-making capacity, providing written informed consent within 30 days prior to enrollment.
  • Age ≥18 years and ≤75 years.
  • ECOG performance status of 0-1, and expected to tolerate lying supine for half an hour.
  • Have undergone radical surgery for cervical cancer (procedure: radical hysterectomy + pelvic lymphadenectomy ± para-aortic lymphadenectomy) or surg…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →